TCGA-E2-A15O-01A-11R-A115-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 10
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.360
- MYC_TARGETS_V2+0.310
- G2M_CHECKPOINT+0.290
- ESTROGEN_RESPONSE_LATE+0.240
- MYC_TARGETS_V1+0.240
- WNT_BETA_CATENIN_SIGNALING+0.140
- DNA_REPAIR+0.130
- ESTROGEN_RESPONSE_EARLY+0.110
- MITOTIC_SPINDLE+0.070
- SPERMATOGENESIS+0.050
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.550
- KRAS_SIGNALING_UP-0.410
- ALLOGRAFT_REJECTION-0.400
- HEDGEHOG_SIGNALING-0.400
- COAGULATION-0.390
- INTERFERON_GAMMA_RESPONSE-0.390
- COMPLEMENT-0.380
- ANDROGEN_RESPONSE-0.370
- HYPOXIA-0.350
- ANGIOGENESIS-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0RL-01A-11R-A084-07 | — | B | 0.889 |
| 2 | BSR_15_0056_E1_S102 | — | B | 0.887 |
| 3 | TCGA-A8-A09C-01A-11R-A00Z-07 | — | B | 0.883 |
| 4 | BS_9V633J1X | medulloblastoma | — | 0.880 |
| 5 | SRR2016967 | — | — | 0.875 |
| 6 | 20050053.LumB | — | B | 0.874 |
| 7 | TCGA-EW-A6SA-01A-21R-A32P-07 | — | B | 0.873 |
| 8 | C3L-04013 | — | cohortMD1 | 0.871 |
| 9 | TCGA-E2-A105-01A-11R-A10J-07 | — | B | 0.869 |
| 10 | BS_9V633J1X | Med | Medulloblastoma | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.310 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.240 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.070 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.040 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.040 | Inavolisib | — uncovered |